Published in Lancet on January 19, 2008
Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation (2014) 2.11
Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med (2012) 1.71
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int (2011) 1.43
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One (2011) 1.06
In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost (2011) 1.03
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci (2014) 0.95
Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost (2011) 0.93
Rationally designed multitarget agents against inflammation and pain. Curr Med Chem (2013) 0.91
Nonsteroidal Anti-Inflammatory Drugs and the Kidney. Pharmaceuticals (Basel) (2010) 0.89
The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol (2013) 0.88
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? Eur J Clin Pharmacol (2008) 0.88
The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology (2014) 0.87
High density micromass cultures of a human chondrocyte cell line: a reliable assay system to reveal the modulatory functions of pharmacological agents. Biochem Pharmacol (2011) 0.84
New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling. Mol Cell Biol (2012) 0.83
Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea. J Am Heart Assoc (2014) 0.81
NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species. Oxid Med Cell Longev (2015) 0.80
Analgesic targets: today and tomorrow. Inflammopharmacology (2009) 0.79
COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One (2014) 0.78
Fish oil, but not soy bean or olive oil enriched infusion decreases histopathological severity of acute pancreatitis in rats without affecting eicosanoid synthesis. Inflammation (2011) 0.77
Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009-2010. Am J Cardiovasc Drugs (2017) 0.77
[New substances and applications for postoperative pain therapy]. Schmerz (2008) 0.76
Pain-novel targets and new technologies. Front Pharmacol (2014) 0.75
Ibuprofen arginate retains eNOS substrate activity and reverses endothelial dysfunction: implications for the COX-2/ADMA axis. FASEB J (2016) 0.75
Naproxen Twice Daily Versus as Needed (PRN) Dosing: Efficacy and Tolerability for Treatment of Acute Ankle Sprain, a Randomized Clinical Trial. Asian J Sports Med (2013) 0.75
Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke. Prostaglandins Other Lipid Mediat (2015) 0.75
Use of ibuprofen sustained release for treating osteoarthritic pain: findings from 15 general medical practices in Egypt. Open Access Rheumatol (2014) 0.75
[Cardiovascular complications with cyclooxygenase inhibitors : Myths and facts]. Z Rheumatol (2010) 0.75
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J (2004) 2.75
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Circulating microRNAs as novel biomarkers for platelet activation. Circ Res (2013) 2.22
Pharmacology and therapeutic potential of interferons. Pharmacol Ther (2012) 1.76
Intestinal injury and endotoxemia in children undergoing surgery for congenital heart disease. Am J Respir Crit Care Med (2011) 1.57
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart (2010) 1.57
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A (2002) 1.44
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J (2005) 1.18
Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J (2005) 1.18
Role of TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia. J Appl Physiol (1985) (2007) 1.18
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol (2009) 1.13
Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle. Respir Res (2005) 1.12
Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites. J Biol Chem (2009) 1.12
Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance. Mol Pharmacol (2005) 1.11
Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol (2009) 1.10
Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med (2010) 1.10
Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med (2007) 1.09
Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res (2013) 1.08
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol (2005) 1.08
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One (2011) 1.06
Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNFalpha in macrophages: role of TLRs in synergy between the two. Br J Pharmacol (2006) 1.04
Innate immunity in human embryonic stem cells: comparison with adult human endothelial cells. PLoS One (2010) 1.02
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol (2007) 1.01
Role of shear stress in endothelial cell morphology and expression of cyclooxygenase isoforms. Arterioscler Thromb Vasc Biol (2010) 1.00
Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci U S A (2005) 0.99
Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol (2009) 0.99
Scanning ion conductance microscopy: a convergent high-resolution technology for multi-parametric analysis of living cardiovascular cells. J R Soc Interface (2011) 0.98
Toll-like receptor 2 is essential for the sensing of oxidants during inflammation. Am J Respir Crit Care Med (2008) 0.97
Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol (2002) 0.97
Cyclo-oxygenase-2 inhibitors and cardiovascular events. Lancet (2002) 0.96
Not so EEZE: the 'EDHF' antagonist 14, 15 epoxyeicosa-5(Z)-enoic acid has vasodilator properties in mesenteric arteries. Eur J Pharmacol (2004) 0.95
Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost (2009) 0.94
Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol (2003) 0.93
Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-α. Gut (2012) 0.93
Inflammatory transcriptome profiling of human monocytes exposed acutely to cigarette smoke. PLoS One (2012) 0.92
Proteome-wide analysis and CXCL4 in systemic sclerosis. N Engl J Med (2014) 0.92
Crucial role of TNF receptors 1 and 2 in the control of polymicrobial sepsis. J Immunol (2009) 0.91
Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ (2012) 0.90
The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. Biochem Biophys Res Commun (2006) 0.90
COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Biol (2006) 0.89
Novel role for P2X receptor activation in endothelium-dependent vasodilation. Br J Pharmacol (2004) 0.88
LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One (2013) 0.88
The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One (2010) 0.87
Heme oxygenase is expressed in human pulmonary artery smooth muscle where carbon monoxide has an anti-proliferative role. Eur J Pharmacol (2003) 0.87
Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. Mol Pharmacol (2002) 0.86
Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A (2013) 0.86
Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by gram-positive and gram-negative bacteria in human airway smooth muscle cells. Respir Res (2008) 0.85
COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J (2008) 0.85
PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha--brief report. Arterioscler Thromb Vasc Biol (2009) 0.85
Carbon monoxide inhibits endothelin-1 release by human pulmonary artery smooth muscle cells. Eur J Pharmacol (2004) 0.85
Homeostatic role of Toll-like receptor 4 in the endothelium and heart. J Cardiovasc Pharmacol Ther (2007) 0.85
Stem cell-derived endothelial cells for cardiovascular disease: a therapeutic perspective. Br J Clin Pharmacol (2013) 0.84
A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses. PLoS One (2012) 0.84
Gram-positive and Gram-negative bacteria synergize with oxidants to release CXCL8 from innate immune cells. Mol Med (2008) 0.83
Transition from placental to air breathing stimulates haem-oxygenase-1 expression without functional consequence for pulmonary vascular adaptation in pigs and mice. Br J Pharmacol (2005) 0.83
Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. Biochem Biophys Res Commun (2013) 0.83
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J (2006) 0.82
Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. Cytokine (2002) 0.82
Endothelium-dependent relaxation and endothelial hyperpolarization by P2Y receptor agonists in rat-isolated mesenteric artery. Br J Pharmacol (2003) 0.82
Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J Pharmacol Exp Ther (2004) 0.82
Viral Toll Like Receptor activation of pulmonary vascular smooth muscle cells results in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial hypertension. Biochem Biophys Res Commun (2012) 0.81
Nitric oxide supports atrial function in sepsis: relevance to side effects of inhibitors in shock. Eur J Pharmacol (2002) 0.80
Reduced endothelial dependent vasodilation in vessels from TLR4(-/-) mice is associated with increased superoxide generation. Biochem Biophys Res Commun (2011) 0.80
Shape and compliance of endothelial cells after shear stress in vitro or from different aortic regions: scanning ion conductance microscopy study. PLoS One (2012) 0.80
Pulmonary endothelium dependent vasodilation emerges after birth in mice. Eur J Pharmacol (2007) 0.79
Identification and characterization of a dysfunctional cardiac myocyte phenotype: role of bacteria, Toll-like receptors, and endothelin. Shock (2007) 0.79
Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test. FASEB J (2013) 0.78
Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells. PLoS One (2012) 0.78
Type II nitric oxide synthase activity is cardio-protective in experimental sepsis. Eur J Pharmacol (2003) 0.78
Evidence that pulmonary vascular pathology explains the decline in lung function associated with interferon α based therapies for chronic hepatitis C virus. J Viral Hepat (2013) 0.77
A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. J Pharmacol Toxicol Methods (2012) 0.77
Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC? Proc Natl Acad Sci U S A (2003) 0.76
Reply to Ricciotti et al.: Evidence for vascular COX isoforms. Proc Natl Acad Sci U S A (2013) 0.76
Cytokine modulation of granulocyte macrophage-CSF and granulocyte-CSF release from stimulated vascular smooth muscle cells. Eur J Pharmacol (2002) 0.76
HIF, stretching to get control of VEGF. Clin Sci (Lond) (2003) 0.75
Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. Eur J Pharmacol (2002) 0.75
Cyclooxygenase and cytokine regulation in lung fibroblasts activated with viral versus bacterial pathogen associated molecular patterns. Prostaglandins Other Lipid Mediat (2013) 0.75